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Opiate Addiction and Considerations for Anesthesia
Robert Saltanovitz RN, BSN, CCRN
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Pathophyiology of 
Addiction
The amygdala attributes emotional value to cues. This 
complex brain structure also plays a critical role in mood 
regulation and stress reactivity during withdrawal. Studies 
have demonstrated that the volume of the amygdala is reduced 
in opiate abusers which can lead to abnormalities in the 
cognitive memory task and decision making. In opiate users 
have reward tolerance due to an upregulation of dopamine 
receptors in the amygdala. There is increased dopaminergic 
neuron activity, yet release of dopamine is reduced. This leads 
to a hypersensitivity to pain as well as increased likelihood for 
patients to be pleasure seeking, that is extenuated during 
times of stress Sadat-Shirazi et al., 2018) 
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According to the Center for Disease 
and Prevention from 1999 to 2017 
around 218,000 Americans have died 
from prescription opioid overdoses. 
Deaths from opioid prescription related 
overdoses were five times greater in 2017 
then in 1999. Prescription opioids are 
prescribed for moderate-to-severe pain, 
after surgery or injury, or for health 
conditions such as cancer.
Due to the high risk for addiction, 
there has been a push by the government 
to promote awareness and promote 
stricter guidelines for prescription and 
alternative options to treat pain.
From 2006 to 2017 There has been a 
19% reduction opioid prescriptions. 
Despite this reduction, in 2017 there has 
been almost 58 opioid prescriptions 
written for every 100 Americans. The 
average number days per prescription 
continues to increase at about 18 days per 
prescription.
Forty-six people die every day from 
opioid prescriptions. Prescriptions 
account for 35% of all opioid overdose 
deaths. Most common drugs involved in 
overdose deaths include:
• Methadone
• Oxycodone
• Hydrocodone
Of those who died from opioid deaths:
• Overdose was more likely for those 
over 65 years of age.
• Rates were higher among non-
Hispanic and American Indians
• Per 100,000 people men died at a 
rate of 6.1 and women 4.2 ("Centers 
for Disease Control and Prevention," 
2018). 
(Younger et al., 2012)
Common Myths to Avoid
(Koepke et al., 2018) (Evans & Cahill, 2016) (Younger et al., 2012) 
Multimodal Options for Anesthesia Providers
Signs and Symptoms of 
Opioid Addiction 
The mesocortical dopamine system is a 
prominent system in the brain’s reward 
pathway. This pathway is activated in 
opioid users through activation of 
dopamine receptors that causes the “high” 
sensation. 
In the Ventral tegmental area, 
dopaminergic neurons innervate the 
nucleus accumbens. Opioids inhibit 
GABAergic interneurons located in the 
ventral tegmental area, this leads to 
activation of dopamine neurons and 
increase dopamine in the nucleus 
accumbens. The role of the nucleus 
accumbens is to translate motivational 
signals from the limbic system into goal-
oriented behavior and self-control (Sadat-
Shirazi et al., 2018) 
Opioid abuse
• Vomiting
• Pruritus
• Sweating
• Twitching
• Miosis
• Loss of appetite
• Drowsiness
• Respiratory 
Depression 
• Coma
• Needle marks 
(Coluzzi et al., 2017) 
Opioid withdrawal
• Dysphoric mood
• Nausea or vomiting
• Lacrimation
• Rhinorrhea
• Muscle aches
• Pupillary dilation
• Piloerection
• Sweating
• Diarrhea
• Yawning
• Fever
• Insomnia 
Evaluation for Preoperative Patients 
Nurses and nurse anesthetists will encounter patients with known and 
unknown opioid use. It is essential to properly evaluate patients so that 
the proper measures can be taken to properly treat their pain before, 
during, and post operatively while reducing the risk for surgical morbidity 
and mortality. Key points to consider:
1. Always consider the question: “Is my patient an opioid user or 
abuser?”
2. Always obtain details for the type of opiate, the duration of use, 
dose, and timing of last dose.
3. Recognize symptoms of opioid abuse and withdrawal as quickly as 
possible.
4. Identify population at risk.
5. Obtain complete history, including physical and diagnostic studies
6. Assess for common comorbidities in addicted patients.
7. Consider coexisting psychiatric disorders.
8. Avoid prejudices and assure the patient.
9. Keep in mind fears the patient has
10. Develop a plan for perioperative pain medication(Coluzzi et al., 
2017).
Gray matter volume decrease in the amygdala following one month of daily morphine
Exposure. Bar graph showing percent volumetric change from baseline in the amygdala for the
placebo group (left bar) and morphine group (right bars). Dark gray bars indicate the post medication
period, and light gray indicates the follow-up period. Amygdala volume is significantly decreased after    
morphine exposure,
and the decreased volume is maintained 4.7 months later at the follow-up period. The
placebo group shows no change in amygdala volume. (c) Post-hoc scatterplot showing
relationship between total morphine consumed (x axis) and percent change in right
amygdala volume (y axis) in the morphine group. One outlier showed no amygdala change
over time.
Gray matter volume increase in the hypothalamus following one month of daily morphine exposure. (a) Sagittal 
view (x = +1) of volume increase in the caudal aspect of the hypothalamus (average volume increase = 3.1%). 
(b) Same hypothalamus cluster presented in coronal plane and (c) in sagittal plane. (d) Bar graph showing 
percent volumetric change from baseline in the hypothalamus for the placebo group (left bar) and morphine 
group (right bars). Dark gray bars indicate the post-medication period, and light gray indicates the follow-up 
period. Hypothalamus volume is significantly increased after morphine exposure, and the increased volume is 
maintained 4.7 months later at the follow-up period. The placebo group shows no significant change in 
hypothalamus volume. (e) Post-hoc scatterplot showing relationship between total morphine consumed (x axis) 
and percent change of hypothalamic volume (y axis) in the morphine group.
• Nonpharmacological interventions
• Education, Rest, ice, 
compression, 
elevation. Cooling 
and heating 
(Johnson & Patel, 
2019)
Anesthesia providers can utilize a variety of nonopioid medications to reduce the overall use of opiates required 
for patients with an opioid tolerance before, during, and post-operatively.
• Acetaminophen
• Metabolite of medication works on brain and spinal cord to help reduce amounts of opioids 
required for pain reduction.
• Nonsteroidal anti-inflammatory drugs
• Reduces prostaglandin release which reduces inflammation and thus pain.
• Ketamine
• Studies show this medication works on N-methyl-D-aspartate receptor involved in the pain 
pathway. Patients required fewer opioids during surgery while on ketamine.
• Gabapentin and pregabalin
• Medication agonise alpha2 receptors, thus decreasing pain signal transmission.
• Local Anesthetics
• Work by blocking sodium channels of nerve fibers, there-by inhibiting the conduction of 
sensory and motor nerve impulses.  These can be further classified into regional nerve blocks, 
spinals, epidurals, and infiltration. These are very promising in reducing overall opioid 
requirements. The FDA recently granted permission of liposomal local anesthetics that allow 
for slow release pain relief to decrease opioid use post-operatively. 
• Transcutaneous electrical nerve stimulation
• Being used more frequently. Involves electrical stimulation to sensory nerves that activate 
inhibiting centers of the central nervous system.
It is important for anesthesia providers to remain empathetic and see the 
situation of addiction from the patient’s point of view. Often times the patients 
are from a lower social economic background and have many co-morbidities. 
Often providers will experience a disjunct with a patient’s expectations for 
pain management and the reality of what is available for their pain 
management. The current climate places many restrictions on opioid 
prescriptions, this can make it difficult when determining the best options to 
adequately care for a patient’s needs. Current research shows that there 
burnout caring for patients when addicted to opioids, because providers want 
to care for the patient, but are not properly trained to utilize other options to 
treat patients with chronic pain. The prevalence of poverty among chronic 
pain patients requires that providers see their job differently. More advocacy 
for improving patients access to resources and provide for patients basic needs 
is an important step in adjunct with reducing opiate usage. There are many 
socio-economic components that many patients with chronic pain cannot 
access that many providers do not realize due to their privilege in socio-
economic status. Physiotherapy, massage, exercise, and mental health access 
may be great alternatives for patients with chronic pain that a provider can 
utilize or advocate for. It is important as providers to lobby and vote for out 
patients to have access to these alternative therapies to reduce opioid use and 
abuse (Webster et al., 2019).
1. Buprenorphine or methadone provides analgesia.
2. Opioids for analgesic will cause relapse for patients at risk for 
addiction.
3. Patients that require additional opioids for analgesia may cause 
respiratory depression and central nervous system depression.
4. Patient-Controlled Analgesia is inadequate for opioid tolerant 
patients post-operatively (Coluzzi et at., 2017).
